1. A double-blind randomized trial of adefovir dipivoxil in Chinese subjects with HBeAg-positive chronic hepatitis B.
- Author
-
Zeng M, Mao Y, Yao G, Wang H, Hou J, Wang Y, Ji BN, Chang CN, and Barker KF
- Subjects
- Adenine therapeutic use, Adolescent, Adult, China epidemiology, DNA, Viral genetics, Double-Blind Method, Female, Follow-Up Studies, Hepatitis B virus genetics, Hepatitis B, Chronic epidemiology, Hepatitis B, Chronic virology, Humans, Immunosuppressive Agents, Incidence, Male, Middle Aged, Treatment Outcome, Adenine analogs & derivatives, Antiviral Agents therapeutic use, Hepatitis B e Antigens immunology, Hepatitis B virus immunology, Hepatitis B, Chronic drug therapy, Organophosphonates therapeutic use
- Abstract
Four hundred and eighty Chinese subjects with hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) were enrolled in a multicenter, double-blind, randomized, placebo-controlled study of adefovir dipivoxil (ADV) 10 mg once daily. There was a significant difference in reduction of serum hepatitis B virus (HBV) DNA after 12 weeks between subjects who received ADV and those who received the placebo (3.4 and 0.1 log10 copies/mL, respectively, P < .001). Further reductions in serum HBV DNA and increases in the proportion of subjects with an HBV DNA level of at most 10(5) copies/mL, with HBV DNA undetectable, and with ALT normalization were observed in ADV-treated subjects at week 52 (median HBV DNA reduction of 4.5 log(10) copies/mL, 67% with HBV DNA
- Published
- 2006
- Full Text
- View/download PDF